Arrowhead’s Zodasiran: Strong Mechanistic Fit for HoFH Faces Commercial Hurdles from Missing Outcomes Data

Arrowhead Completes Enrollment for Phase III Zodasiran Trial

Arrowhead Pharmaceuticals has completed patient enrolment for its global Phase III YOSEMITE study of zodasiran, an investigational RNA interference (RNAi) therapeutic for homozygous familial hypercholesterolaemia (HoFH). HoFH is a rare inherited disorder characterized by elevated LDL-C and early onset cardiovascular disease. The randomized, double-blind, placebo-controlled study enrolled 70 adolescent and adult patients (aged 12+) who are already on maximum tolerated lipid-lowering treatments. Participants were randomized 2:1 to receive 200mg zodasiran or placebo every three months. The primary outcome measure is the percent change in fasting LDL-C from baseline to month 12. The trial is expected to conclude in mid-2027, after which Arrowhead plans to seek regulatory approval based on the results. Zodasiran has received Orphan Drug Designation from the US FDA for HoFH.

• The YOSEMITE study is a global, multi-centre, randomised, double-blind, placebo-controlled Phase III trial. It successfully enrolled 70 participants, exceeding the initial target of 60, demonstrating significant interest. The study focuses on adolescent and adult patients (12 years and older) with genetically or clinically confirmed HoFH, who are already receiving maximum tolerated lipid-lowering therapies, addressing a population with high cardiovascular risk and limited treatment options.
• Participants in the YOSEMITE study were assigned in a 2:1 ratio to receive either 200mg of zodasiran or a placebo. The treatment is administered every three months over four dosing periods. The primary outcome measure for the trial is the percent change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline to month 12, providing a clear metric for assessing the drug's efficacy in managing HoFH.
• Zodasiran functions as an RNA interference (RNAi) therapeutic, specifically designed to reduce the production of angiopoietin-like protein 3 (ANGPTL3). This targeted mechanism aims to lower triglycerides and atherogenic lipoproteins, as observed in previous studies. The investigational drug has also been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for HoFH, underscoring its potential to address an unmet medical need in a rare disease population.

Addressing the Critical Unmet Needs in Homozygous Familial Hypercholesterolaemia

Despite significant therapeutic advances, achieving recommended LDL-cholesterol (LDL-C) targets in patients with Homozygous Familial Hypercholesterolaemia (HoFH) remains a formidable challenge. These limitations span the entire patient journey, from initial diagnosis to long-term management with both conventional and novel agents, leaving a high residual burden of atherosclerotic cardiovascular disease (ASCVD).

• Suboptimal Efficacy of Conventional Therapies: A primary challenge is the difficulty in achieving target LDL-C reductions with standard lipid-lowering drugs. Many patients are far from recommended goals, partly due to the high prevalence of statin intolerance (estimated between 7% and 29%) and the lower efficacy of alternative oral therapies like ezetimibe. Consequently, most HoFH patients require multiple concomitant therapies to manage their severe hypercholesterolemia.

• Burdens of Lipoprotein Apheresis (LA): For patients refractory to pharmacological treatments, LA is often required but is associated with a significant negative impact on quality of life. Patients report that the procedure is time-consuming, uncomfortable, and difficult to cope with, leading to an increased risk of depression. Furthermore, treatment is often suboptimal, with many patients undergoing infrequent sessions and expressing unwillingness to increase the frequency.

• Gaps in Diagnosis and Identification: The HoFH care pathway is critically hampered by widespread underdiagnosis. Traditional diagnostic tools, such as the Dutch Lipid Clinic Network criteria, depend on clinical data that is frequently missing in real-world practice. This is compounded by an ongoing failure to implement systematic cascade screening to identify affected relatives, representing a major gap between patient identification and therapy initiation.

• Limitations of Novel Therapeutic Classes: While promising, newer therapies are not without their own challenges. The efficacy of LDLR-dependent agents like PCSK9 inhibitors is highly variable and contingent on the patient's residual LDLR function. For potentially curative gene therapies, significant hurdles remain, including delivery efficiency, immunogenicity, the precision of gene editing, and a substantial economic burden.

• Systemic and Implementation Barriers: Inconsistent and fragmented care delivery undermines effective management. There is a lack of a standardized therapeutic approach across different treatment centers. Moreover, the real-world adoption of proven strategies, such as EHR-integrated clinical decision support and multidisciplinary lipid clinics, remains low, slowing the translation of evidence into practice.

• Persistent Residual Cardiovascular Risk: A crucial unmet need is that even with optimal and intensive medical therapy, many HoFH patients still develop coronary atherosclerosis and suffer major cardiovascular events. This highlights that current treatment paradigms are often insufficient to fully mitigate the profound and lifelong cardiovascular risk inherent to the disease.

Zodasiran's Safety and Tolerability Profile Across Clinical Development

Zodasiran, an investigational GalNAc-conjugated RNA interference (RNAi) therapeutic that selectively silences hepatic ANGPTL3 expression, has demonstrated a consistently favorable safety and tolerability profile across its Phase 1 and 2 clinical development program. Across studied indications—including mixed dyslipidemia, familial hypercholesterolemia, and populations with limited LDL receptor function such as homozygous familial hypercholesterolemia—zodasiran has been well-tolerated, with minimal adverse events reported alongside dose-dependent and durable lipid-lowering effects. This tolerability profile has held even in patient populations addressing residual atherosclerotic cardiovascular disease (ASCVD) risk, supporting its potential utility in LDL receptor-independent lipid-lowering strategies.

Comparative data reinforce this favorable safety signal. A network meta-analysis encompassing 14 trials and 5,646 participants found that most ANGPTL3-targeting and siRNA-based drugs, including zodasiran, showed no significant differences from placebo in terms of adverse events or serious adverse events. Within this analysis, zodasiran also demonstrated modest reductions in Lp(a) levels of approximately 15%, alongside its established lipid-lowering efficacy. Relative to other ANGPTL3-targeting agents, zodasiran may offer additional advantages in hepatic specificity, dosing frequency, and duration of action, positioning it favorably within this emerging therapeutic class.

Despite this encouraging early profile, important evidence gaps remain. Long-term safety and cardiovascular outcome data for zodasiran are currently lacking, as existing studies have been limited to Phase 1 and 2 trials without extended follow-up on hard clinical endpoints. Future research priorities include large-scale trials designed to evaluate clinical outcomes, optimize patient selection criteria, and explore cost-effective strategies to support broader access to this promising RNAi-based lipid-lowering agent.